Effect of diabetes mellitus type 2 and sulfonylurea on colorectal cancer development: a case-control study.
Colorectal neoplasms
Sulfonylurea
Type 2 diabetes
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
30
06
2024
accepted:
23
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Colorectal cancer (CRC) is a significant global health concern, with studies estimating a rise in new cases to 2.5 million by 2035. Type 2 diabetes (T2D) is also a growing issue, with an estimated 642 million adults affected by 2040. However, the relationship between T2D, its medications, and CRC remains unclear. This case-control study includes 810 controls without CRC and 684 cases with CRC admitted to Rasoul-Akram and Firouzgar Hospitals from September 2019 to 2023. Adjusted and unadjusted odds ratios (OR) were calculated to investigate the effect of T2D and sulfonylurea consumption on the chance of CRC development, using univariate and multivariate logistic regression analyses. The relationship between T2D and the clinicopathological features of the tumor was investigated. The results show that the effect of T2D on CRC is significant based on unadjusted OR (OR = 1.39, CI = 1.07, 1.81) and insignificant in adjusted OR (OR = 0.67, CI = 0.37, 1.20). The effect of sulfonylurea consumption on CRC was significant in both unadjusted (OR = 2.39, CI = 1.40, 4.09) and adjusted ORs (OR = 2.35, CI = 1.12, 4.91). All analyses related to the relationship between T2D and tumor clinicopathological characteristics were insignificant. This study found an insignificant association between type 2 diabetes and the chance of CRC development in an adjusted state. Sulfonylurea consumption was also associated with a higher chance of CRC development among patients with T2D. These findings have implications for clinical practice and public health strategies in CRC prevention for patients with T2D.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Colorectal cancer (CRC) is a significant global health concern, with studies estimating a rise in new cases to 2.5 million by 2035. Type 2 diabetes (T2D) is also a growing issue, with an estimated 642 million adults affected by 2040. However, the relationship between T2D, its medications, and CRC remains unclear.
MATERIALS AND METHODS
METHODS
This case-control study includes 810 controls without CRC and 684 cases with CRC admitted to Rasoul-Akram and Firouzgar Hospitals from September 2019 to 2023. Adjusted and unadjusted odds ratios (OR) were calculated to investigate the effect of T2D and sulfonylurea consumption on the chance of CRC development, using univariate and multivariate logistic regression analyses. The relationship between T2D and the clinicopathological features of the tumor was investigated.
RESULTS
RESULTS
The results show that the effect of T2D on CRC is significant based on unadjusted OR (OR = 1.39, CI = 1.07, 1.81) and insignificant in adjusted OR (OR = 0.67, CI = 0.37, 1.20). The effect of sulfonylurea consumption on CRC was significant in both unadjusted (OR = 2.39, CI = 1.40, 4.09) and adjusted ORs (OR = 2.35, CI = 1.12, 4.91). All analyses related to the relationship between T2D and tumor clinicopathological characteristics were insignificant.
CONCLUSION
CONCLUSIONS
This study found an insignificant association between type 2 diabetes and the chance of CRC development in an adjusted state. Sulfonylurea consumption was also associated with a higher chance of CRC development among patients with T2D. These findings have implications for clinical practice and public health strategies in CRC prevention for patients with T2D.
Identifiants
pubmed: 39465354
doi: 10.1186/s12876-024-03477-4
pii: 10.1186/s12876-024-03477-4
doi:
Substances chimiques
Sulfonylurea Compounds
0
Hypoglycemic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
382Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
doi: 10.1136/gutjnl-2015-310912
pubmed: 26818619
Sninsky JA, Shore BM, Lupu GV, Crockett SD. Risk factors for colorectal polyps and cancer. Gastrointest Endosc Clin N Am. 2022;32(2):195–213.
doi: 10.1016/j.giec.2021.12.008
pubmed: 35361331
Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184–92.
doi: 10.1056/NEJMoa043792
pubmed: 15917383
Rezende LF, Lee DH, Keum N, Nimptsch K, Song M, Lee IM, Eluf-Neto J, Ogino S, Fuchs C, Meyerhardt J, Chan AT. Physical activity during adolescence and risk of colorectal adenoma later in life: results from the nurses’ Health Study II. Br J Cancer. 2019;121(1):86–94.
doi: 10.1038/s41416-019-0454-1
pubmed: 31114018
pmcid: 6738055
Guo CG, Ma W, Drew DA, Cao Y, Nguyen LH, Joshi AD, Ng K, Ogino S, Meyerhardt JA, Song M, Leung WK. Aspirin use and risk of colorectal cancer among older adults. JAMA Oncol. 2021;7(3):428–35.
doi: 10.1001/jamaoncol.2020.7338
pubmed: 33475710
Hullings AG, Sinha R, Liao LM, Freedman ND, Graubard BI, Loftfield E. Whole grain and dietary fiber intake and risk of colorectal cancer in the NIH-AARP Diet and Health Study cohort. Am J Clin Nutr. 2020;112(3):603–12.
doi: 10.1093/ajcn/nqaa161
pubmed: 32619213
pmcid: 7458778
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–51.
doi: 10.1016/S0140-6736(17)30058-2
pubmed: 28190580
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Reviews Endocrinol. 2018;14(2):88–98.
doi: 10.1038/nrendo.2017.151
Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Clinical Guidelines Committee of the American College of Physicians*. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279–90.
doi: 10.7326/M16-1860
pubmed: 28055075
Centers for Disease Control and Prevention. National Diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US department of health and human services. Centers Disease Control Prev. 2011;201(1):2568–9.
DeMarsilis A, Reddy N, Boutari C, Filippaios A, Sternthal E, Katsiki N, Mantzoros C. Pharmacotherapy of type 2 diabetes: an update and future directions. Metabolism. 2022;137:155332.
doi: 10.1016/j.metabol.2022.155332
pubmed: 36240884
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–87.
doi: 10.1093/jnci/dji375
pubmed: 16288121
La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol. 1997;6(12):1007–10.
Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26:863–76.
doi: 10.1007/s10654-011-9617-y
pubmed: 21938478
Sun L, Yu S. Diabetes mellitus is an independent risk factor for colorectal cancer. Dig Dis Sci. 2012;57:1586–97.
doi: 10.1007/s10620-012-2059-x
pubmed: 22302244
Murphy N, Song M, Papadimitriou N, Carreras-Torres R, Langenberg C, Martin RM, Tsilidis KK, Barroso I, Chen J, Frayling TM, Bull CJ. Associations between glycemic traits and colorectal cancer: a mendelian randomization analysis. JNCI: J Natl Cancer Inst. 2022;114(5):740–52.
doi: 10.1093/jnci/djac011
pubmed: 35048991
pmcid: 9086764
Pan XF, He M, Yu C, Lv J, Guo Y, Bian Z, Yang L, Chen Y, Wu T, Chen Z, Pan A. Type 2 diabetes and risk of incident cancer in China: a prospective study among 0.5 million Chinese adults. Am J Epidemiol. 2018;187(7):1380–91.
doi: 10.1093/aje/kwx376
pubmed: 29304221
pmcid: 6153481
Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2258–68.
doi: 10.1158/1055-9965.EPI-13-0429
pubmed: 24042261
Bu WJ, Song L, Zhao DY, Guo B, Liu J. Insulin therapy and the risk of colorectal cancer in patients with type 2 diabetes: a meta-analysis of observational studies. Br J Clin Pharmacol. 2014;78(2):301–9.
doi: 10.1111/bcp.12350
pubmed: 25099257
pmcid: 4137822
Ng CA, Jiang AA, Toh EM, Ng CH, Ong ZH, Peng S, Tham HY, Sundar R, Chong CS, Khoo CM. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. Int J Colorectal Dis. 2020;35:1501–12.
doi: 10.1007/s00384-020-03676-x
pubmed: 32592092
Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18(2):148–56.
doi: 10.1634/theoncologist.2012-0302
pubmed: 23345544
pmcid: 3579598
Azizi H, Delpisheh A, Sayehmiri K, Asadollahi K, Esmaeili ED, Sharbafi J. Risk of Colorectal Cancer in Type2 Diabetic patients. Med J Tabriz Univ Med Sci. 2016;38(4):56–65.
Overbeek JA, Kuiper JG, van der Heijden AA, Labots M, Haug U, Herings RM, Nijpels G. Sex-and site-specific differences in colorectal cancer risk among people with type 2 diabetes. Int J Colorectal Dis. 2019;34:269–76.
doi: 10.1007/s00384-018-3191-7
pubmed: 30421309
Lawler T, Walts ZL, Steinwandel M, Lipworth L, Murff HJ, Zheng W, Andersen SW. Type 2 diabetes and colorectal cancer risk. JAMA Netw Open. 2023;6(11):e2343333.
doi: 10.1001/jamanetworkopen.2023.43333
pubmed: 37962884
pmcid: 10646729
Ma Y, Yang W, Song M, Smith-Warner SA, Yang J, Li Y, Ma W, Hu Y, Ogino S, Hu FB, Wen D. Type 2 diabetes and risk of colorectal cancer in two large US prospective cohorts. Br J Cancer. 2018;119(11):1436–42.
Grega T, Vojtechova G, Gregova M, Zavoral M, Suchanek S. Pathophysiological characteristics linking type 2 diabetes Mellitus and Colorectal Neoplasia: this paper is dedicated to the 70th anniversary of the founding of Physiologia Bohemoslovaca (currently Physiological Research). Physiol Res. 2021;70(4):509.
doi: 10.33549/physiolres.934631
pubmed: 34062073
pmcid: 8820551
Al-Qahtani WS, Al-Olayan E, Albani FG, Suliman RS, Aljarba NH, Al-Humaidhi EM, Almurshedi AS, Domiaty DM, Alduwish MA, Al-Otaibi AM, Elasbali AM. Utility of KRAS gene and clinicopathological features in the assessment of the risk of type 2 diabetes in the etiology of colon cancer. Global Med Genet. 2020;7(02):035–40.
doi: 10.1055/s-0040-1714415
Del Puerto-Nevado L, Santiago‐Hernandez A, Solanes‐Casado S, Gonzalez N, Ricote M, Corton M, Prieto I, Mas S, Sanz AB, Aguilera O, Gomez‐Guerrero C. Diabetes‐mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction. Mol Oncol. 2019;13(9):1887–97.
doi: 10.1002/1878-0261.12531
pubmed: 31199051
pmcid: 6717745
Peng WF, Bai F, Shao K, Shen LS, Li HH, Huang S. The key genes underlying pathophysiology association between the type 2-diabetic and colorectal cancer. J Cell Physiol. 2018;233(11):8551–7.
doi: 10.1002/jcp.26440
pubmed: 29319171
Budzynska K, Passerman D, White-Perkins D, Rees DA, Xu J, Lamerato L, Schooley S. Diabetes mellitus and hyperglycemia control on the risk of colorectal adenomatous polyps: a retrospective cohort study. BMC Fam Pract. 2018;19:1–8.
doi: 10.1186/s12875-018-0835-1
Yarmolinsky J, Bouras E, Constantinescu A, Burrows K, Bull CJ, Vincent EE, Martin RM, Dimopoulou O, Lewis SJ, Moreno V, Vujkovic M. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a mendelian randomisation analysis. Diabetologia. 2023;66(8):1481–500.
doi: 10.1007/s00125-023-05925-4
pubmed: 37171501
pmcid: 10317892
Shin CM, Kim N, Han K, Kim B, Jung JH, Oh TJ, Lee DH. Anti-diabetic medications and the risk for colorectal cancer: a population-based nested case-control study. Cancer Epidemiol. 2020;64:101658.
doi: 10.1016/j.canep.2019.101658
pubmed: 31887708
Li S, Wang Y, Zhang D, Wang H, Cui X, Zhang C, Xin Y. Gliclazide reduces Colitis-Associated Colorectal Cancer formation by Deceasing Colonic inflammation and regulating AMPK-NF-κB signaling pathway. Dig Dis Sci. 2024;69(2):453–62.
doi: 10.1007/s10620-023-08211-w
pubmed: 38103106